Literature DB >> 10100285

One-center experience with cyclosporine in refractory nephrotic syndrome in children.

A Singh1, C Tejani, A Tejani.   

Abstract

Uncontrolled or refractory nephrotic syndrome (NS), seen in a variety of glomerular disorders, leads to end-stage renal disease (ESRD). This study describes the use and efficacy of cyclosporine (CSA) for the treatment of refractory NS in 83 children seen over a 10-year period. The histological diagnosis leading to the NS was focal segmental glomerulosclerosis (FSGS) in 51% (n = 42), IgM nephropathy in 20% (n = 17), membranoproliferative glomerulonephritis in 10% (n = 8), lupus nephritis in 6% (n = 5), human immunodeficiency virus (HIV) nephropathy in 5% (n = 4), minimal change disease in 7% (n = 6), and membranous nephropathy in 1% (n = 1) of patients. During CSA therapy the mean proteinuria of the study population decreased from 5.14 g/24 h (4.80 g/m2 per 24 h) to 1.23 g/24 h (0.92 g/m2 per 24 h) (P < 0.001), the mean serum albumin increased from 2.13 g/dl to 3.53 g/dl (P < 0.001), the mean serum cholesterol decreased from 364 mg/dl to 223 mg/dl (P < 0.001), and the mean serum creatinine increased from 0.77 mg/dl to 1.2 mg/dl (P < 0.01). When analyzed by histological diagnosis, similar significant trends of reduction in proteinuria were seen in all but the lupus group. There was a rise in serum creatinine following the use of CSA in patients with FSGS, lupus nephritis, and HIV nephropathy; however the elevated serum creatinine was only significant in patients with FSGS. At the end of the study period, 20 patients had reached ESRD, of which 11 had FSGS, 5 had lupus nephritis, and 4 were patients with HIV nephropathy. Fifty-four patients were in remission at the end of the study period (48 with proteinuria < 100 mg/24 h and 6 with proteinuria < 500 mg/24 h). In conclusion, among children with refractory NS, CSA induced a remission in a large proportion. However toxicity, as noted by the rise in serum creatinine, was observed in several patients. Since this toxicity may be drug induced or a natural progression of the disease, careful monitoring and close follow-up are essential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100285     DOI: 10.1007/s004670050557

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

1.  Single-dose daily administration of cyclosporin A for refractory nephrotic syndrome.

Authors:  Masanobu Kudo; Koji Tsugawa; Hiroshi Tanaka
Journal:  Pediatr Nephrol       Date:  2005-05-05       Impact factor: 3.714

2.  Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome.

Authors:  Amr El-Husseini; Fathy El-Basuony; Ihab Mahmoud; Ahmed Donia; Hussein Sheashaa; Alaa Sabry; Nabil Hassan; Nagy Sayed-Ahmad; Mohamed Sobh
Journal:  Eur J Clin Pharmacol       Date:  2005-12-23       Impact factor: 2.953

3.  Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis.

Authors:  Asiri S Abeyagunawardena; Neil J Sebire; R Anthony Risdon; Michael J Dillon; Lesley Rees; William Van't Hoff; Pallegoda V Kumarasiri; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2006-12-05       Impact factor: 3.714

4.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

5.  Minimal change disease with IgM+ immunofluorescence: a subtype of nephrotic syndrome.

Authors:  Sarah J Swartz; Karen W Eldin; M John Hicks; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2009-02-14       Impact factor: 3.714

Review 6.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

8.  Therapies for steroid-resistant nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig
Journal:  Pediatr Nephrol       Date:  2008-03-27       Impact factor: 3.714

9.  Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.

Authors:  Kim Loeffler; Manjula Gowrishankar; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

Review 10.  A 20-year history of childhood HIV-associated nephropathy.

Authors:  Patricio E Ray; Lian Xu; Tamara Rakusan; Xue-Hui Liu
Journal:  Pediatr Nephrol       Date:  2004-08-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.